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The heterogeneous nuclear ribonucleoprotein K (hnRNP K) protein is an RNA-binding protein involved in many processes that
compose gene expression. K protein is upregulated in the malignant processes and has been shown to modulate the expression of
genes involved in mitogenic responses and tumorigenesis. To explore the possibility that there are alternative isoforms of K protein
expressed in colon cancer, we amplified and sequenced K protein mRNA that was isolated from colorectal cancers as well as from
normal tissues surrounding the tumours. Sequencing revealed a single G-to-A base substitution at position 274 that was found in
tumours and surrounding mucosa, but not in individuals that had no colorectal tumour. This substitution most likely reflects an RNA
editing event because it was not found in the corresponding genomic DNAs. Sequencing of RNA from normal colonic mucosa of
patients with prior resection of colorectal cancer revealed only the wild-type K protein transcript, indicating that G274A isoform is
tumour related. To our knowledge, this is the first example of an RNA editing event in cancer and its surrounding tissue, a finding that
may offer a new diagnostic and treatment marker.
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Colorectal cancer is one of the most frequent causes of morbidity and
mortality from malignancy in Europe and North America (Didkowska
et al, 2003; Jemal et al, 2005). Although improvements have been
made in the surgical and nonsurgical therapies of colorectal cancer,
the mortality remains high. A better understanding of the molecular
basis of the disease is needed to develop new diagnostic tools and
improve ways to prevent and treat colorectal cancer.
The heterogeneous nuclear ribonucleoprotein K (hnRNP K)
protein is an ancient RNA-binding protein (Bomsztyk et al, 2004).
Since it was originally identified as a component of the hetero-
geneous nuclear ribonucleoprotein particles, K protein has been also
found in the cytoplasm and mitochondria where it is involved in
multiple processes that compose gene expression (Bomsztyk et al,
2004). K protein contains three K homology (KH) domains that
mediate RNA/DNA binding and the K-interactive (KI) region that
recruits many protein partners (Bomsztyk et al, 1997, 2004).
K protein is upregulated in malignant cells (Dejgaard et al, 1994;
Mandal et al, 2001; Ostrowski and Bomsztyk, 2003; Li et al, 2004),
and it regulates the expression of genes involved in mitogenic
responses, indicating that it has a direct role in cancerogenesis
(Michelotti et al, 1995, 1996; Ostrowski and Bomsztyk, 2003;
Ostrowski et al, 2004). We have shown that following mitogenic
stimulation, K protein is recruited to gene loci known to be
upregulated in malignant states, including c-myc (Ostrowski et al,
2003). This finding is consistent with the observed shift of K
protein to the nuclei in neoplasms (Ostrowski and Bomsztyk, 2003).
As a result of alternative splicing, there are several known
isoforms of K protein (Dejgaard et al, 1994; Makeyev and Liebhaber,
2002). To explore the possibility that there are isoforms of K protein
enriched in cancer, we sequenced cDNA encoding K protein from
colorectal adenocarcinoma and compared it to the cDNAs from the
surrounding normal mucosa. Sequencing revealed novel G274A
polymorphism found in mRNA, but not in the genomic DNA. Thus,
this polymorphism most likely reflects mRNA editing event, which
changes alanine (Ala) to threonine (Thr) at the end of KH1 domain.
Beside colorectal adenocarcinoma, G274A isoform of K protein
mRNA was also found in a few thyroid cancers, but not in normal
tissues surrounding breast, thyroid or renal carcinomas, nor in
normal or in inflammation-altered colonic mucosa from the
patients with inflammatory bowel disorders. These data identify
novel RNA editing phenomenon specific to colorectal carcinoma
that may be involved in the processes of tumour formation and
development and may serve as a diagnostic marker.
MATERIALS AND METHODS
Tissues
In all, 21 surgically resected colorectal tumours, 18 thyroid
tumours (five follicular, four papillary and nine medullary
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scarcinomas), 20 breast carcinomas and 10 clear-cell renal
carcinomas used in this study were obtained at the Maria
Skłodowska-Curie Memorial Cancer Center and Institute of
Oncology (Warsaw, Poland). Fresh surgical specimens were
immediately placed on ice and transported to the pathology
laboratory. Following gross examination, samples of adjacent
tissue and tumours were dissected and immediately frozen at
 801C. The presence of normal and tumour tissue was assessed by
histological evaluation of tissue adjacent to the fragments used for
RNA and DNA isolation.
In 10 patients who underwent surgical treatment (but no
adjuvant chemo- or radiotherapy) for colorectal carcinomas,
mucosal biopsies were taken colonoscopically from macroscopi-
cally normal mucosa adjacent to the anastomosis, 12 to 26 months
after the surgery. Also, in four patients with Crohn’s disease and in
five with ulcerative colitis, mucosal biopsies were taken colono-
scopically from macroscopically normal colonic mucosa and
mucosa involved in inflammatory process. The presence of normal
mucosa and colonic inflammation typical for the inflammatory
bowel disorder was confirmed histologically.
The protocol of the study was approved by local ethics
committees, and written informed consent was obtained from all
patients.
RNA analysis
Total RNA and genomic DNA tissue samples were purified using
RNeasy Mini Kit and DNeasy Tissue Kit (Qiagen, Hilden,
Germany), respectively. RNA was reverse transcribed using
SuperScript II RT (GIBCO-BRL, Gaithersburg, MD, USA) and
random hexamer primers in 20ml of volume as per the
manufacturer’s protocol. The full-length cDNA, a 453-bp fragment
of cDNA or 301-bp fragment of genomic DNA encoding K protein
were amplified using Pfu Turbo DNA polymerase and primers, as
listed in the Table 1; primer location is shown in Figure 1.
The polymerase chain reaction (PCR)-amplified DNA fragments
were T/A subcloned into pCR2.1 plasmid, and the resultant vectors
were transformed into chemically competent TOP10 cells. Plasmid
DNA was isolated from randomly chosen bacterial clones and
sequenced using ABI Prism 377 automated DNA sequencing
system (Applied Biosystems, Foster City, CA, USA).
Since G-to-A substitution at position 274 in K protein cDNA
creates Sca1 restriction enzyme site (AGTACT), restriction
fragment length polymorphism (Jenkins, 2004) was also used to
screen cDNA fragments for the modification. Fragment (453bp) of
cDNA inserted into plasmid vector was amplified, the PCR product
was purified with QIAquick PCR Purification Kit (Qiagen),
digested with ScaI and analysed on 2.5% agarose gel.
K protein phosphorylation in vitro
The wild-type and G274A-mutated cDNA of K protein were
subcloned into pET-28(þ) expression vector (Novagen, Madison,
WI, USA), and the plasmids were transformed into Escherichia coli
BL21 DE3 pLysS cells (Novagen). Bacterially expressed recombi-
nant proteins were purified by affinity chromatography using Ni-
NTA agarose (Qiagen) according to the manufacturer’s protocol.
The correct point-mutant product was confirmed by sequence
analysis using liquid chromatography–electrospray mass spectro-
metry with collisional fragmentation (LC–ESI–MS–MS/MS).
Purified wild-type and mutated K proteins were phosphorylated
in vitro by casein kinase-1 (CK1), casein kinase-2 (CK2) or their
mixture in the buffer containing 25mM Tris, pH¼7.5, 200mM
NaCl, 0.1mM ATP (with or without [g-
32P]-ATP) and 10mM MgCl2
for 20min at 301C. Proteins phosphorylated in the presence of
[g-
32P]-ATP were separated by sodium dodecyl sulphate–poly-
acrylamide gel electrophoresis and visualised using a phosphor-
imager. Proteins phosphorylated with cold ATP were digested with
trypsin, and the resulting phosphopeptides were analysed by mass
spectrometry. Peptide mixture was applied to nano-high-perfor-
mance liquid chromatography RP-18 column, directly coupled to
nano-Z-spray ion source of quadrapole time-of-flight electrospray
mass spectrometer (Waters) working in the regimen of data-
dependent MS to MS/MS switch. The output list of parent and
daughter ions was submitted to database search using MASCOT
(MatrixScience) program. Peptide identification and the presence
of their covalent modifications were verified by inspection of
parent mass fragmentation patterns using programs MassLynx
(Waters) and ProteinProspector.
Protein modelling
The three-dimensional (3D) structures of the KH1 domain of
protein K and its mutant A92T, and of the KH2 domain were
predicted by homology modelling using SWISS-MODEL (Peitsch,
1996), using the coordinates of the KH3 domain as the template
(crystallographic structure 1khm in Protein Data Bank). The
structure of the entire K protein was modelled by joining the
structures of the individual domains by the linker in an extended
conformation. The preliminary model of KH1–RNA complex was
obtained by copying the coordinates of the RNA molecule from the
KH3–RNA structure obtained by NMR (Braddock et al, 2002) and
optimising the interactions with the protein by the steepest descent
Table 1 Primers used to amplify K protein cDNA
Primer sequence 50-30 Expected length of PCR product Ta (1C)
Full-length cDNA GCTTCAGTTCTGCTCTGCAAGGAT-fwd 1619 57
ACACCTCAAATGCAGAACACCTATGA-rev
RFLP fragment AATGGTGAATTTGGTAAACGCC-fwd 453 57
TTTAGCACCTTTGACCCCAATAAT-rev
Genomic fragment ATTGGGTATAAAACAAAATGCATGTG-fwd 301 54
AAACATTCCCCCCTCATATTGTC-rev
PCR¼polymerase chain reaction; RFLP¼restriction fragment length polymorphism.
345 6 7 8 9
AATGGTGAATTTGGTAAACGCC TTTAGCACCTTTGACCCCAATAAT
G/A
ATTGGGTATAAAACAAAATGCATGTG AAACATTCCCCCCTCATATTGTC
7 6 7
G/A
cDNA
Genomic
DNA
Exons
Exon Intron Intron
A
B
Figure 1 Position of the primers used for the amplification of hnRNP K
cDNA (A) and genomic DNA (B) fragments.
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smethod, as implemented in HyperChem 7.1 (Hypercube Inc.,
Gainesville FL, USA).
Putative phosphorylation sites in K protein were predicted using
the NetPhos 2.0 server (http://www.cbs.dtu.dk/services/NetPhos/)
(Blom et al, 1999). The 3D model of protein K was used to identify
those potential phosphorylation sites, which are not buried in the
protein core, and thus are likely to be modified in the native
protein.
Statistical analysis Differences between groups were analysed by
the Mann–Whitney test and paired two-tailed t-test using
Statistica PL software. A P-value of o0.05 was considered to be
statistically significant.
RESULTS
Pilot sequencing of the full-length cDNA encoding K protein
isolated from three pairs of colon adenocarcinoma and the normal
mucosa surrounding the tumour revealed G274A polymorphism
present in all samples (Accession number AY911506). To further
explore this finding, cDNAs were generated from RNA isolated
from several pairs of tissues (normal/pathological) that were taken
from patients with colorectal cancer. A 453-bp fragment of K
protein cDNA was amplified by PCR, T/A subcloned into plasmid
vector and six to 14 bacterial clones from each transformation
were randomly chosen for sequencing (Figure 2).
As shown in Table 2, G274A polymorphism was found in K
protein cDNA generated from RNA that was isolated from 15 out
of 21 (71%) colorectal cancers and from all normal mucosa that
surrounded these colon tumours. The median percentage of K
protein transcripts carrying G274A polymorphism within an
individual tissue specimen were significantly higher in normal
mucosa surrounding tumours than in corresponding colorectal
carcinomas (54 vs 8% of all sequenced clones; Po0.001). One
explanation for such a difference could be that tumour induces
G274A RNA editing. Alternatively, normal mucosa in response to
tumour may produce a signal for the RNA editing. The relative
frequency of the clones with G274A polymorphism did not appear
to correlate with any of the variables that were tested, such as
sex, age, tumour location, size, type, differentiation, presence of
metastases and stage according to Astler–Coller, Jass prognostic
criteria. This observation suggests that G274A polymorphism is a
good candidate to be used as a universal and specific marker for
the diagnosis of colorectal adenocarcinoma.
The above studies suggested that the G274A polymorphism is
related to colorectal adenocarcinoma. To test this relationship
further, we sequenced K protein cDNA from normal mucosa taken
A
B
453 bp
228/225 bp
1       2
Sequence of cDNA generated from wild-type mRNA
Sequence of cDNA generated from edited mRNA
2       1
Uncut
Figure 2 Analysis of K protein transcript. (A) Sequences of individually cloned cDNA fragments from wild-type and edited mRNA of K protein. ScaI
restriction site is indicated by box. (B) Agarose gel electrophoresis of PCR-generated fragments from cDNA encoding K protein that were digested with
(right) or without (left) Sca1 restriction enzyme. Fragments (453bp) of K protein cDNA wild type (line 1) and with G274A polymorphism (line 2) were
digested with Sca1.
Table 2 Summary of G274A RNA polymorphism analysis
Patient groups
Number of
tissue pairs
Number of tissues with
G274A RNA isoform
Normal tissue/pathological tissue
Number of sequenced clones:
total (G274A RNA)
Normal tissue/pathological tissue
Colon cancer 21 21/15 229 (120)/235 (51)
Colon cancer after surgical treatment 10 0/NA 80 (0)/NA
Crohn’s disease or ulcerative colitis 9 0/0 54 (0)/54 (0)
Thyroid cancer 18 0/2 108 (0)/108 (5)
Breast cancer 20 0/0 120 (0)/120 (0)
Renal cancer 10 0/0 80 (0)/80 (0)
NA¼not applicable.
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scolonoscopically from the sites of surgical anastomosis from 10
patients with prior resection of colorectal carcinoma, including
two patients whose tissues were previously tested positive for the
G274-A polymorphism in both cancer and surrounding mucosa.
In all those patients, only the G274 wild-type isoform was found.
Similarly, in nine patients with inflammatory bowel disease,
sequencing analysis of biopsy specimens of the involved and
unaffected mucosa revealed only the wild-type K protein mRNA.
To test if the G274A polymorphism is specific to colorectal
adenocarcinoma, we examined pairs of neoplastic and normal
surrounding tissues from breast, kidney and thyroid. Except for
two thyroid cancers, only the wild-genotype K protein RNA
isoform was found in these specimens (Table 2). The fact that the
G274A polymorphism was also found in thyroid cancers suggests
that the RNA editing could be also induced by other tumours,
although with much lower efficiency.
To exclude the possibility that the G274A polymorphism was
generated by reverse transcriptase (RT)–PCR, we repeated the
entire genotyping experiment in all colorectal patients. The second
series of RNA extraction and sequencing confirmed the presence
of previously determined polymorphism in both normal and
cancer samples (data not shown). This indicates that G274A
polymorphism was not introduced by PCR.
Next, we tested if G274A polymorphism is found in K protein
gene. To do that, we analysed 78 samples of genomic DNA
(Figure 1) obtained from tumour and matched surrounding
normal tissue samples extracted from the same 21 patients with
colorectal cancer and 18 patients with thyroid cancer. The PCR
products were subcloned into plasmid vector, and five clones from
each bacterial transformation were sequenced. Of 390 independent
clones analysed, none contained the G274A polymorphism. Since
there is only one K protein gene transcribed from 13kb locus
localised on long arm of chromosome 9, and K protein’s
pseudogenes have the same G274 base and are not expressed, we
conclude that the G274A polymorphism most likely results from
an RNA editing event.
G274A polymorphism found in K protein mRNA substitutes Ala
codon by Thr codon. One consequence of such amino-acid
substitution within K protein could be a creation of new
phosphorylation site. Reversible phosphorylation of proteins is a
fundamental mechanism of the regulation of cellular functions.
Analysis of K protein amino-acid sequence revealed several
putative sites that meet the criteria for phosphorylation by
serine–threonine kinases: calmodulin CII, CK1, CK2, glycogen
synthase kinase 3, p34cdc2, p70S6 and protein kinase C (PKC).
Indeed, K protein has been shown to be phosphorylated by several
kinases, including Src, Lck, PKCd, extracellular signal-regulated
protein kinse, c-Jun NH2-terminal kinase and CK2, each
phosphorylating one or more sites (Bomsztyk et al, 2004).
Three-dimensional modelling of K protein indicates that Thr92,
introduced as a result of G274A editing of mRNA, is located on the
surface of the molecule (Figure 3; panels A–C), and thus may
represent a new phosphorylation site for CK1. We tested this
possibility next.
As shown in Figure 4, CK1 effectively phosphorylates both the
wild-type protein and A92T isoform, whereas phosphorylation
mediated by CK2 was much weaker. However, the strongest signals
were generated by the use of mixture of both enzymes CK1 and
CK2 in phosphorylation reactions. The intensity of phosphoryla-
tion was significantly stronger for Ala92Thr-mutated protein than
the wild-type K protein.
To prove that increased phosphorylation of mutated K protein
reflects phosphorylation of Thr92, we used mass spectrometry
analysis. The wild-type and mutated proteins phosphorylated by
both CK1 and CK2 were digested with trypsin. The resulting
peptides were analysed by LC–ESI–MS–MS/MS mass spectro-
metry. Amino-acid sequencing identified the 87- to 103-amino-
acid wild-type K protein peptide (ILSISADIETIGEILKK) (bold A
indicates Ala at position 92) and the mutated peptide (ILSISTDIE-
TIGEILKK) (bold T indicates substituted Thr at position 92)
molecules with the masses 1843.07 and 1873.08Da, respectively, as
well as with 80 and 160Da above the predicted masses. The
Figure 3 Structural modelling of wild-type, Thr92 and phospho-Thr92K protein isoforms. (A–C) model of the KH1 domain of the K protein, its A92T
isoform and the A92T isoform phosphorylated at Thr92, respectively. The protein is shown in the space fill representation, with helices shown in orange,
strands in green and loops in light grey. Residue 92 (Ala, Thr and phospho-Thr, respectively) is coloured according to the following scheme: C atoms: dark
grey; O atoms: red; N atoms: blue; and P atoms: orange. (D–F) The Coulomb electrostatic potential mapped onto the surface of each variant of the KH1
domain and expressed as a colour range (from red,  6kT, to blue, þ6kT). (G–I) Model of RNA interacting with KH1 domain of hnRNP K protein.
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saddition of a phosphate group increases the mass of peptides by
80Da. Thus, as shown in Table 3, the A92T isoform was much
more efficiently phosphorylated by these kinases, an alteration that
most likely reflects direct phosphorylation of Threonine 92.
In the wild-type peptide, there are three potential phosphoryla-
tion sites adjacent to Ala92, Ser89, Ser91 and Thr96, but only
Thr96 fits the criteria for phosphorylation by CK2. Thus, the
characteristic mass shift of 0.7% of the wild-type peptide molecules
likely reflects P-Thr96. The Thr92 residue, introduced by RNA
editing, also meets the criteria for phosphorylation by either CK1
or CK2. Therefore, 22.5% of mutated peptide molecules with added
80Da might reflect P-Thr92, and other 2.5% of phosphopeptides
are consistent with both P-Thr92 and P-Thr96. Thus, MS studies
provide evidence that Thr92 residue is either itself phosphorylated
or enhances phosphorylation of the neighbouring Ser/Thr
residues.
K protein binding to RNA reflects synergistic interaction
between three KH domains and cognate RNA where each KH
domain binds one of three C-rich boxes (Paziewska et al, 2004). As
shown in Figure 3, the structural changes resulting from the
putative phosphorylation of Thr92 does not disrupt the 3D-fold of
the KH domain (panels A–C). However, the phosphorylation can
introduce significant negative charge on the protein surface
(panels D–F), leading to alteration of K protein RNA-binding
activity. Independent of whether Thr92 is directly phosphorylated
or changes phosphorylation of other neighbouring residues,
these observations indicate that A92T polymorphism may alter K
protein function in response to extracellular signals that engage
kinase cascades. The putative location of the RNA molecule
(panels G–I) (based on solved structure of the KH3 single-
stranded DNA complex; Braddock et al, 2002) is shown to visualise
the region of protein–RNA interactions that may be influenced by
the Ala to Thr substitution and by the phosphorylation. Although
not shown in this figure, because of the lack of the appropriate
modelling template, the extended 30-end of the RNA molecule
could directly interact with the modified region.
DISCUSSION
RNA editing is a co- or post-transcriptional process (Gott and
Emeson, 2000) that modifies the genetic information at the
transcript level, either by insertion or deletion of nucleotides, or
by base modification. Enzymatic base modification of RNA
sequences was originally discovered in the mitochondrial RNA of
trypanosomes (Turelli and Trono, 2005). In mammals, the two
major types of RNA base modifications are associated with various
physiological processes, including neurotransmission, lipid meta-
bolism and adaptive immunity (Turelli and Trono, 2005). They
include A-to-I and C-to-U editing (Gott and Emeson, 2000; Maas
and Rich, 2000; Davidson, 2002).
RNA editing is mediated by RNA–protein complexes, which
contain small guiding RNAs and several associated proteins
(Decatur and Fournier, 2003). A-to-I RNA editing occurs on
unspliced mRNA templates and is mediated by adenosine
deaminases acting on double-stranded RNAs). The partially
double-stranded RNA that involves exonic and intronic sequences
or a hairpin structure is thought to be essential for this type of
RNA editing (Maas et al, 2003). The primate cytidine deaminases
family represents 12 enzymes (Turelli and Trono, 2005). Adeno-
sine deaminases acting on double-stranded RNAs are responsible
for site-specific RNA editing of both coding and noncoding region
sequences (Yang et al, 2005). Adenosine deaminases acting on
double-stranded RNA-mediated RNA editing occurs within coding
or untranslated RNAs and appears to be widespread in human
nervous system (Bhalla et al, 2004; Blow et al, 2004). Adenosine
deaminases acting on double-stranded RNA-mediated RNA
editing is essential for normal development and cell viability,
and altered editing is associated with inflammation and several
neurological disorders (Geslain and Ribas de Pouplana, 2004;
Eisenberg et al, 2005).
Until now, a few C-to-U edits and single examples of purine-to-
pyrimidine and pyrimidine-to-purine RNA edits were described
within the open-reading frame of cellular and viral transcripts
(Gott and Emeson, 2000; Maas and Rich, 2000; Gerber and Keller,
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CK1     +      +       − − +       +       − −
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K protein
32P-K protein
Thr92
Ala92
Thr92
Ala92
Thr92
Ala92
Thr92
Ala92
P<0.01
P<0.01
P<0.05
Figure 4 Phosphorylation of K protein and its mutant by casein kinases
(CK). Recombinant wild-type and Thr92-mutated K proteins were
phosphorylated using CK1 (CK1d, rat, recombinant) or CK2 (CKII purified
from rat liver) or both kinases.
32P-labelled proteins eluted from the beads
were analysed by sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis followed by autoradiography (upper panel) and densitometry of
the Coomassie-stained band of the same gel (lower panel) using Molecular
Imager FX Pro Plus (Bio-Rad). The
32P signals were normalised to
Coomassie band intensities and expressed as relative levels (diagram).
Results shown in the graph represent means7s.d. of three independent
experiments.
Table 3 Summary of peptide (87–103aa) counts derived from the wild-type and A92T-mutated K protein that were phosphorylated by CK1 and CK2 in
vitro and analysed by mass spectrometry
ILSISADIETIGEILKK mass
1843.07Da (% of total)
ILSISTDIETIGEILKK mass
1873.08Da (% of total)
Total peptide counts
a 1569 (100) 3360 (100)
Number of peptide molecules with the mass 80Da above predicted 10 (0.7) 755 (22.5)
Number of peptide molecules with the mass 160Da above predicted ND 86 (2.5)
aa¼amino acids; CK1¼casein kinase 1; CK2¼casein kinase 2; ND¼not detected.
aTotal peptide counts is the number of detected peptide molecules with the predicted mass
as well as with the masses 80 and 160Da above predicted. Italic A or T in peptides sequences indicates Ala or substituted thr at position 92, respectively.
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s2001; Schaub and Keller, 2002; Decatur and Fournier, 2003; Vitali
et al, 2005). Cytidine deamination was recognised as an important
defence mechanism against retroviral infection, including human
and simian immunodeficiency viruses, equine infectious anaemia
virus and murine leukaemia virus (Turelli and Trono, 2005).
Based on the discrepancy between the mRNA (cDNA) and
genomic sequences, we have identified G274A RNA editing of K
protein transcript specific to adenocarcinomas of the colon.
Similar G-to-A editing events were also described in mRNA of
the human EAA5 (GluR7) receptor (Nutt et al, 1994) and in human
immunovirus-1 mRNAs isolated from chronically infected H9 cells
(Bourara et al, 2000). Mechanisms of G-to-A RNA editing are
unknown. No consensus was detected in surrounding sequences of
viral RNA that underwent G-to-A editing and there were no
consistent secondary structures evident in these regions (Bourara
et al, 2000). Nonetheless, analysis of K protein RNA sequence
around the editing site revealed a potential hairpin conformation
(Figure 5B). Whether this secondary structure guides G274A
editing remains to be determined.
RNA editing that involves changes in mRNA sequences may
create new start or stop codons, new open-reading frames or
alteration in encoded amino acids. Modification of untranslated
regions of a transcript can alter its stability, transport or
translation, and intronic editing can influence pre-mRNA splicing.
Although RNA editing may change genetic information that, in
turn, may generate genetic instability in neoplasms, only few
examples of such alterations were described in neoplasm. For
example, altered expression of NAT1 (homologous the caboxyl-
terminal translational initiation factor 4G) and NF1 (encoding
neurofibromatosis type 1 protein) that resulted from C-to-U RNA
editing was described in malignant tissues (Aasheim et al, 1994). In
human carcinomas of the stomach, pancreas, large intestine and
liver alterations in the expression of an RNA-specific cytidine
deaminase, APOBEC-1, that is involved in RNA editing were also
reported (Lee et al, 1998). Therefore, RNA editing found in
malignant tissues may be a cause or a consequence of tumorigen-
esis.
Although the method used to estimate the frequency of the RNA
editing events allowed only for a semiquantitative analysis, the
polymorphism of K protein mRNA seems to be more common in
the surrounding normal mucosa than in colorectal cancer. Since
G274A polymorphism was absent in colon mucosa from patients
who underwent a colon resection for colorectal cancer, or from
patients with inflammatory bowel disease, or in neoplastic and
normal surrounding tissues from breast, kidney and thyroid,
we hypothesise that it may be a field defect in colorectal mucosa
surrounding the cancer where tumour releases a signal for the
RNA editing. It is also possible that G274A isoform of K protein is
a defence reaction of normal tissues to the neighbouring tumour.
Future experiments will show whether RNA editing of K protein
contributes to the development of colorectal cancer.
As K protein is upregulated in tumour cells (Dejgaard et al,
1994; Mandal et al, 2001; Ostrowski and Bomsztyk, 2003; Li et al,
2004) and modulates the expression of genes involved in mitogenic
responses (Michelotti et al, 1995, 1996; Mandal et al, 2001;
Ostrowski et al, 2004), altering its properties and introduction of a
new phosphorylation site could make K protein either more or less
conducive for the cellular processes that lead to tumorigenic state.
If so, identification of this novel tumour-associated K protein
isoform may prove to be a useful diagnostic, prognostic and/or
therapeutic indicator.
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